FDA Approves Foundayo (Orforglipron) Under Commissioner’s National Priority Voucher (CNPV) Program
In a move that signals a significant shift in both obesity treatment and regulatory efficiency, the U.S. Food and Drug Administration (FDA) has officially announced that it approves Foundayo (orforglipron), a new oral medication designed to combat obesity. The approval, granted on April 1, 2026, is not merely a win for patients seeking weight management … Read more